MG
LABT

Marex Group’s Lakewood-Amedex Biotherapeutics LABT Stock Holding History

Marex Group’s Portfolio LABT Stock Details LABT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Buy
+48,167
New +$826K ﹤0.01% 1041

Other funds holding LABT

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Marex Group's LABT Position: Q2 2026 in Review

Marex Group opened a new position in Lakewood-Amedex Biotherapeutics (LABT) in Q2 2026: 48,167 shares worth $151K. The stake represents ﹤0.01% of the portfolio and ranks #1041 among its holdings.

6 funds tracked by Wall St. Rank hold LABT as of Q2 2026.

  • Marex Group held 48,167 shares of Lakewood-Amedex Biotherapeutics worth $151K as of Q2 2026.
  • Lakewood-Amedex Biotherapeutics was a new Marex Group position in Q2 2026.
  • Lakewood-Amedex Biotherapeutics made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #1041 holding.
  • 6 funds tracked by Wall St. Rank held Lakewood-Amedex Biotherapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.